Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507768 | 1.00 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL7805532 | 0.92 | ALDH1A1 (0.59) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL854197 | 0.92 | ALDH1A1 (0.59) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL31333614 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL14464189 | 0.86 | ALDH1A1 (0.79) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL9984672 | 0.86 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL3032231 | 0.86 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL7805673 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL22505448 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL9987106 | 0.85 | TDP1 (0.74) | ALDH1A1KMT2ALMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-1976938-A | Thienopyrazole derivatives having PDE7 inhibitory activity | ASUBIO PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | ALDH1A1 2864/4885KMT2A 3266/4885LMNA 4644/4885 |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | ALDH1A1 2534/4885KMT2A 548/4885LMNA 2478/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885KMT2A 448/4885LMNA 3004/4885 |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885KMT2A 448/4885LMNA 3004/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | ALDH1A1 2864/4885KMT2A 3266/4885LMNA 4644/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | ALDH1A1 3400/4885KMT2A 1132/4885LMNA 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.